Preparation method and application of colorectal cancer microenvironment responsive nano-drug capable of resisting bacterial adhesion
By grafting N-acetylgalactosamine and OxPt on dendritic molecule polyethyleneimine, and using the assembly technology of azobenzene and cyclodextrin, the nanodrug OGPA/PEG-CD was formed, and the chemotherapy of colorectal cancer cells was solved. The problems of drug resistance and Fn adhesion have achieved effective drug release and anti-tumor effects in tumor environment.
Patent Information
- Application Number
- CN202310566482.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-19
- Publication Date
- 2024-11-22
AI Technical Summary
Colorectal cancer cells are resistant to the chemotherapeutic drug oxaliplatin (OxPt), resulting in poor treatment effect. The adhesion of Gram-negative anaerobic bacteria Fn in the intestinal flora promotes tumor cell proliferation and immune microenvironment plastic, reduce the therapeutic effect of chemotherapy drugs.
N-acetylgalactosamine (GalNAc) and OxPt are grafted on dendritic molecule polyethyleneimine and utilize the host-guest interaction of azobenzene and cyclodextrin to be used to cyclodextrin to graft it with polyethylene glycol-cyclodextrin (PEG-CD) assembly forms anti-Fn adhesion and anti-tumor nanodrug OGPA/PEG-CD, which reverses CRC's resistance to chemotherapy drugs.
In the presence of weak acid environment and overexpressed glutathione, nanodrug structural fissures interpret the release of divalent Pt, inhibit Fn adhesion, reverse CRC resistance, and improve tumor treatment effect.
Smart Images

Figure CN118987259A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of nanomaterial self-assembly, and specifically relates to utilizing the host-guest interaction between azobenzene and cyclodextrin to graft oxaliplatin (OxPt), N-acetylgalactosamine (GalNAc) and 4-dimethylaminoazobenzene-4'-thioisocyanate (ITPADA) onto dendritic molecule polyethyleneimine and then assemble with polyethylene glycol-cyclodextrin (PEG-CD) to obtain a colorectal cancer microenvironment responsive nanomedicine having both anti-bacterial adhesion and anti-tumor effects. Background Art
[0002] Colorectal cancer (CRC) is a common digestive tract malignancy in clinical practice, which seriously threatens human health. Studies have shown that the occurrence of colorectal cancer is multifactorial, including environmental and genetic factors, and it is also closely related to dietary habits. Dietary behavior greatly affects the composition of intestinal flora, which in turn affects the susceptibility to intestinal diseases. Recent studies have confirmed that there is a very close relationship between colorectal cancer and intestinal flora, and the World Health Organization has officially recognized that some microorganisms in the intestinal microbiota can cause cancer. Fusobacterium nucleatum (Fn) is a Gram-negative anaerobic bacterium and a core member of the human oral microbiota. However, recent studies have found that Fn is present in large quantities in CRC tumor samples, and its abundance in CRC is much greater than that in normal tissues. Fn can adhere to and colonize in the CRC site, thereby promoting the proliferation and metabolism of CRC cell lines, reshaping the tumor immune microenvironment, and ultimately inducing drug resistance, reducing the therapeutic effect of chemotherapy drugs on CRC.
[0003] Therefore, during the treatment process, antagonists that inhibit Fn adhesion are introduced to reduce its adhesion to CRC cells, thereby reversing the resistance of CRC to chemotherapy drugs caused by Fn and achieving better anti-tumor effects. Summary of the invention
[0004] The purpose of the present invention is to provide a method for preparing a colorectal cancer microenvironment-responsive nanomedicine with anti-bacterial adhesion, which can reverse the resistance of CRC to the chemotherapeutic drug OxPt caused by Fn.
[0005] The technical solution of the present invention is:
[0006] The nano drug (OGPA / PEG-CD) uses dendritic polyethyleneimine (OEI) as a carrier to graft N-acetylgalactosamine (GalNAc), OxPt and ITPADA to obtain OGPA, and assembles OGPA with PEG-CD by using the host-guest interaction of azobenzene group (AZO) and cyclodextrin, and finally obtains the nano drug OGPA / PEG-CD with both anti-Fn adhesion and anti-tumor properties. The drug can reverse the drug resistance of CRC and improve the anti-tumor activity. The preparation and application research methods of the nano drug OGPA / PEG-CD are as follows:
[0007] 1) Prepare nanodrug OGPA / PEG-CD by self-assembly.
[0008] 2) In vitro anti-adhesion studies were carried out using the nanodrug delivery system OGPA / PEG-CD.
[0009] 3) Use the nanodrug delivery system OGPA / PEG-CD to conduct in vitro reversal of drug resistance studies.
[0010] 4) The advantages of the present invention are: the weak acid environment of the tumor site, azoreductase and overexpressed glutathione can promote the cleavage of the nanodrug structure and release the chemotherapy drug OxPt, and promote the reduction of the less toxic tetravalent Pt to the more toxic divalent Pt, and GalNAc can inhibit Fn adhesion to CRC, thereby reversing drug resistance and enhancing the therapeutic effect of CRC. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] 1) Figure 1 Schematic diagram of the assembly route and effect of OGPA / PEG-CD.
[0012] 2) Figure 2 The synthetic route of Pt-COOH, GalNAc-TsCl, OEI-GalNAc, OEI-GalNAc-Pt, and OEI-GalNAc-Pt-AZO.
[0013] 3) Figure 3 These are the H NMR spectra of Pt-COOH, GalNAc-TsCl, OEI-GalNAc, OEI-GalNAc-Pt, and OEI-GalNAc-Pt-AZO.
[0014] 4) Figure 4 The scanning electron microscope image and particle size distribution diagram of OGPA / PEG-CD.
[0015] 5) Figure 5 This is the stability graph of OGPA / PEG-CD in 10% serum solution.
[0016] 6) Figure 6This is the responsive release curve of Pt from OGPA / PEG-CD in buffer solutions with different pH values.
[0017] 7) Figure 7 This is the UV spectrum of OGPA / PEG-CD cleavage in the presence of a reducing agent.
[0018] 8) Figure 8 The survival rates of HCT116 and CT26 tumor cells in different treatment groups, where (+) indicates the presence of Fn and (-) indicates the absence of Fn. DETAILED DESCRIPTION
[0019] The invention uses OEI as a carrier, loads OxPt, GalNAc and ITPADA, and self-assembles with PEG-CD to obtain nanoparticles OGPA / PEG-CD.
[0020] Specific examples of the present invention are given below:
[0021] 1. Synthesis of Pt-COOH
[0022] 500 mg of OxPt was added to a 50 mL round-bottom flask, and 10 mL of acetic acid was added. The mixture was heated in an oil bath at 28° C. with stirring, and hydrogen peroxide (0.1 mL) was added every 30 minutes. The mixture was then stirred for 12-16 hours in the dark.
[0023] 2. Synthesis of GalNAc-TsCl
[0024] Weigh GalNAc (2086 mg) into a 100 mL round-bottom flask, add 20 mL of anhydrous pyridine, weigh p-toluenesulfonyl chloride (TsCl, 2827.7 mg) into a 25 mL round-bottom flask, add 10 mL of anhydrous pyridine, add the TsCl solution in pyridine dropwise into the GalNAc solution in an ice-water bath, and stir at room temperature for 12-16 hours.
[0025] 3. Synthesis of OEI-GalNAc
[0026] GalNAc-TsCl (1740 mg), OEI (1200 mg), and 30 mL of NN-dimethylformamide (DMF) were placed in a 100 mL round-bottom flask and stirred at room temperature overnight for 12-16 hours. The resulting solution was dialyzed with a 1000 kDa dialysis bag and then freeze-dried to obtain a light yellow flocculent product.
[0027] 4. Synthesis of Pt-OEI-GalNAc
[0028] Pt-COOH (200 mg), 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC, 40 mg), N-hydroxysuccinimide (NHS, 109 mg), OEI-GalNAc (230 mg), and anhydrous DMF (30 mL) were added to a 100 mL round-bottom flask and stirred for 24 hours in a dark environment. The resulting solution was dialyzed with a 1500 kDa dialysis bag and then freeze-dried to obtain a yellow flocculent product.
[0029] 5. Synthesis of Pt-OEI-GalNAc-AZO
[0030] Pt-OEI-GalNAc (80 mg), N-methylmorphine (NMM, 10 μL), ITPADA (12 mg), and dimethyl sulfoxide (DMSO, 25 mL) were placed in a 100 mL round-bottom flask and stirred at room temperature in the dark for 24 hours. The resulting solution was dialyzed with a 1500 kDa dialysis bag and then freeze-dried to obtain an orange flocculent product.
[0031] 6.OGPA / PEG-CD
[0032] OGPA and PEG-CD (AZO and CD molar ratio 1:4) were taken and dissolved in water respectively. After being uniformly mixed under ultrasonic conditions, ultrasonication was continued for 10-30 minutes, and the product was lyophilized.
[0033] 7. Co-culture of Colorectal Cancer Cells and Fn
[0034] Take 0.5 mL of trypsin to digest colorectal cancer cells CT26 and HCT116 to obtain a single cell suspension, which is inoculated in a 96-well cell culture plate at a density of 5000 cells / well. After culturing for 18 to 20 hours, the cell confluence rate reaches 60% to 70%; Fn with good growth condition is suspended in RIMP1640 culture medium without fetal bovine serum at an infection multiplicity (MOI) of 50 to 200 to obtain a bacterial suspension; then the bacterial suspension is added to the 96-well plate at a volume of 0.1 mL per well, and after culturing in a constant temperature incubator at CO2 / 37°C for 2-3 hours, the bacterial suspension is aspirated and 0.1 mL of RIMP1640 complete culture medium is added to each well for continued culturing.
[0035] 8. Cell Viability Assay
[0036] CT26 and HCT116 cells were seeded at 5000 cells / well in a 96-well plate and cultured for 24 hours. Different concentrations of OGPA / PEG-CD were added to the 96-well plate co-cultured with the above cells and bacteria. After incubation for 24 hours, 100 μL of MTT solution (5 mg / mL) was added to each well. After 2.5 hours, 100 μL of DMSO was added to each well, and the 96-well plate was gently shaken to dissolve the blue-purple crystalline formazan, and then the absorbance of each well was measured at a wavelength of 570 nm using an ELISA reader to calculate the cell survival rate.
[0037] Figure 1 The figure is a schematic diagram of the assembly route and effect of OGPA / PEG-CD. OGPA and PEG-CD are self-assembled to obtain OGPA / PEG-CD nanoparticles. The nanoparticles reverse the drug resistance of CRC to OxPt caused by Fn and improve the therapeutic effect.
[0038] Figure 2 The synthetic route for preparing OGPA adopts substitution reaction, oxidation reaction, esterification reaction and the like.
[0039] Figure 3 The NMR hydrogen spectra of OGPA, PEG-CD, and OGPA / PEG-CD are shown in Figure 2. The successful preparation of OGPA / PEG-CD can be confirmed by comparison. The particle size distribution shows that the particle size is about 200 nm, which is in line with expectations, proving the successful preparation of 5-FU-LA@PPL nanoparticles.
[0040] Figure 4 Figure 2 is the particle size distribution and scanning electron microscopy image of OGPA / PEG-CD. It can be seen that the particle size is about 180 nm, which is in line with expectations and can prove the successful preparation of OGPA / PEG-CD nanoparticles.
[0041] Figure 5 This is a stability diagram of OGPA / PEG-CD nanoparticles in a solution containing 10% serum, indicating that the nanoparticles are not adsorbed by plasma proteins and have the function of long-term circulation in the blood.
[0042] Figure 6 It is an in vitro drug-responsive release. By comparing the release of Pt in simulated normal environment and tumor microenvironment, it can be seen that the cumulative amount of drug released by the nanoparticle OGPA / PEG-CD in the tumor environment is significantly increased compared with that in the normal environment.
[0043] Figure 7 This is the UV spectrum of the cleavage of OGPA / PEG-CD nanoparticles in the presence of a reducing agent. After adding the reducing agent Na2S2O4, the azo bond breaks, and the nanomicelles disintegrate to release the drug.
[0044] Figure 8It is the result of the effect of OGPA / PEG-CD on CT26 and HCT116 as well as CT26 / Fn and HCT116 / Fn. It can be seen from the figure that OGPA / PEG-CD has obvious therapeutic effects on CT26 and HCT116. After adding Fn, OGPA / PEG-CD and OPG can inhibit Fn adhesion to cells and reverse drug resistance because they contain GalNAc, thus improving the therapeutic effect of colorectal cancer, while OP cannot reverse drug resistance because it does not contain GalNAc.
[0045] It should be noted that the above-described embodiments are only preferred embodiments of the present invention and are only used to further illustrate the present invention, and do not limit the protection scope of the present invention. Any obvious changes that belong to the technical concept of the present invention are also within the protection scope of the present invention.
Claims
1. Preparation and application of a colorectal cancer microenvironment-responsive nanomedicine with anti-bacterial adhesion, characterized by: The nano drug uses dendritic polyethyleneimine (OEI) as a carrier, and obtains OGPA by grafting carboxylated oxaliplatin (Pt-COOH), sulfonylated N-acetylgalactosamine (GalNAc-TsCl) and 4-dimethylaminoazobenzene-4'-thioisocyanate (ITPADA), and then utilizes host-guest interaction and polyethylene glycol-cyclodextrin self-assembly to obtain nanoparticles OGPA / PEG-CD. The preparation steps are as follows: 1) N-acetylgalactosamine is subjected to an esterification reaction with p-toluenesulfonyl chloride, and further a substitution reaction with polyethyleneimine is performed to obtain OEI-GalNAc. Carboxylated oxaliplatin is subjected to an amidation reaction with OEI-GalNAc to obtain OPG, and an azobenzene conjugate OGPA is obtained by a one-step method. 2) OGPA and PEG-CD were dissolved in water respectively, mixed evenly under ultrasonic conditions, and then ultrasonicated for 30 minutes, and then freeze-dried to obtain nanoparticles OGPA / PEG-CD.
2. The preparation and application of a colorectal cancer microenvironment-responsive nanomedicine with anti-bacterial adhesion according to claim 1, characterized in that: The separation method of GalNAc-TsCl is silica gel column chromatography, and the eluent is ethyl acetate / methanol (v / v=9:1).
3. The preparation and application of a colorectal cancer microenvironment-responsive nanomedicine with anti-bacterial adhesion according to claim 1, characterized in that: The separation method of Pt-COOH is silica gel column chromatography, and the eluent is ethyl acetate / methanol (v / v=3:1).
4. The preparation and application of an antibacterial adhesion colorectal cancer microenvironment responsive nanomedicine according to claim 1, characterized in that: The ratio of OGPA to PEG-CD during assembly is azobenzene:cyclodextrin=1:4 (molar ratio).
5. The preparation and application of a colorectal cancer microenvironment-responsive nanomedicine with anti-bacterial adhesion according to claim 1, characterized in that: The OGPA / PEG-CD nanoparticles are collected by freeze drying; the average particle size of the OGPA / PEG-CD nanoparticles is 150-200 nm; and the nanoparticles have a polydispersity of less than 0.
4.
6. Use of the OGPA / PEG-CD nanoparticles according to any one of claims 1 to 5 in a drug for treating colorectal cancer (CRC).
7. The use according to claim 6, characterized in that: The CRC cell lines include HCT116 or CT26.
8. An OGPA / PEG-CD nanoparticle as described in any one of claims 1 to 5 for use in preventing bacterial adhesion to colorectal cancer (CRC).
9. The use according to claim 8, characterized in that: The strain is Fusobacterium nucleatum (Fn); the OGPA / PEG-CD nanoparticles are used to reverse the CRC drug resistance caused by Fn.
10. The use according to claim 9, characterized in that: The chemotherapy drug that produces drug resistance is OxPt or Pt-COOH.
